Vol 4, No 3 (June 24, 2015): Translational Lung Cancer Research

Editorial

Is chest radiation now a classical practice for extensive small cell lung cancer?
Paul Van Houtte, Luigi Moretti, Martine Roelandts
Translational Lung Cancer Research  
2015;
4
(3)
:209-210
.
Consolidative radiation therapy for extensive-stage small cell lung cancer
Lisa Singer, Sue S. Yom
Translational Lung Cancer Research  
2015;
4
(3)
:211-214
.
First-line nivolumab (anti-PD-1) monotherapy in advanced NSCLC: the story of immune checkpoint inhibitors and “the sorcerers apprentice”
Gerald Schmid-Bindert, Tao Jiang
Translational Lung Cancer Research  
2015;
4
(3)
:215-216
.
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutations (JO25567): an open-label, randomized, multicenter, phase II study
Kazushi Yoshida, Yasuhide Yamada
Translational Lung Cancer Research  
2015;
4
(3)
:217-219
.
Anatomic segmentectomy for non-small cell lung cancer: can we believe the hype?
Ernest G. Chan, Jonathan D’Cunha
Translational Lung Cancer Research  
2015;
4
(3)
:220-222
.
Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer— the Holy Grail in cancer treatment?
Ludger Sellmann, Klaus Fenchel, Wolfram C. M. Dempke
Translational Lung Cancer Research  
2015;
4
(3)
:223-227
.

Original Article

18F-FDG-PET/CT in the assessment of pulmonary solitary nodules: comparison of different analysis methods and risk variables in the prediction of malignancy
Ober van Gómez López, Ana María García Vicente, Antonio Francisco Honguero Martínez, Germán Andrés Jiménez Londoño, Carlos Hugo Vega Caicedo, Pablo León Atance, Ángel María Soriano Castrejón
Translational Lung Cancer Research  
2015;
4
(3)
:228-235
.
Prognostic value of Twist in lung cancer: systematic review and meta-analysis
Junli Zeng, Ping Zhan, Guannan Wu, Wen Yang, Wenjun Liang, Tangfeng Lv, Yong Song
Translational Lung Cancer Research  
2015;
4
(3)
:236-241
.

Review Article

Dysregulation of the Met pathway in non-small cell lung cancer: implications for drug targeting and resistance
Joseph J. Sacco, Michael J. Clague
Translational Lung Cancer Research  
2015;
4
(3)
:242-252
.
The past, present and future of immunotherapy against tumor
Tao Jiang, Caicun Zhou
Translational Lung Cancer Research  
2015;
4
(3)
:253-264
.
The radiation techniques of tomotherapy & intensity-modulated radiation therapy applied to lung cancer
Zhengfei Zhu, Xiaolong Fu
Translational Lung Cancer Research  
2015;
4
(3)
:265-274
.
Screening for lung cancer using low-dose computed tomography: concerns about the application in low-risk individuals
Jiu-Wei Cui, Wei Li, Fu-Jun Han, Yu-Di Liu
Translational Lung Cancer Research  
2015;
4
(3)
:275-286
.

Mini-Review

Chitinase-3-like-1/YKL-40 as marker of circulating tumor cells
Gerhard Hamilton, Barbara Rath, Otto Burghuber
Translational Lung Cancer Research  
2015;
4
(3)
:287-291
.

Letter to the Editor

Which patients with extensive stage small-cell lung cancer should and should not receive thoracic radiotherapy?
Berend J. Slotman, Harm van Tinteren
Translational Lung Cancer Research  
2015;
4
(3)
:292-294
.

Meet the Professor1

Professor Robert Pirker: primary prevention and early detection of lung cancer should be strengthened
Melanie C. He
Translational Lung Cancer Research  
2015;
4
(3)
:295-297
.
Professor Helmut H. Popper: the major challenges and potential solutions for future management of lung cancer
Melanie C. He
Translational Lung Cancer Research  
2015;
4
(3)
:298-299
.

Evidence-Based Medicine2

Clinicopathologic characteristics of patients with ROS1 fusion gene in non-small cell lung cancer: a meta-analysis
Qingqing Zhu, Ping Zhan, Xinlin Zhang, Tangfeng Lv, Yong Song
Translational Lung Cancer Research  
2015;
4
(3)
:300-309
.

Expert Consensus

Expert consensus on image-guided radiofrequency ablation of pulmonary tumors—2015 edition
Bao-Dong Liu, Xiu-Yi Zhi
Translational Lung Cancer Research  
2015;
4
(3)
:310-321
.

Disclosure:

1. The series “Meet the Professor” was commissioned by the Editorial office, Translational Lung Cancer Research without any sponsorship or funding.

2. The series “Evidence-Based Medicine” was commissioned by the Editorial office, Translational Lung Cancer Research without any sponsorship or funding.